LEADER 03860nam 22006135 450 001 9910799252203321 005 20251008140702.0 010 $a3-031-33602-X 024 7 $a10.1007/978-3-031-33602-7 035 $a(CKB)29526823000041 035 $a(DE-He213)978-3-031-33602-7 035 $a(MiAaPQ)EBC31230664 035 $a(Au-PeEL)EBL31230664 035 $a(EXLCZ)9929526823000041 100 $a20240104d2023 u| 0 101 0 $aeng 135 $aur||||||||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aBreast Cancer Research and Treatment $eInnovative Concepts /$fedited by Ouissam Al Jarroudi, Khalid El Bairi, Giuseppe Curigliano 205 $a1st ed. 2023. 210 1$aCham :$cSpringer International Publishing :$cImprint: Springer,$d2023. 215 $a1 online resource (VIII, 368 p. 33 illus., 28 illus. in color.) 225 1 $aCancer Treatment and Research,$x2509-8497 ;$v188 311 08$a3-031-33604-6 311 08$a3-031-33601-1 320 $aIncludes bibliographical references. 327 $aAntibody-drug conjugates -- Tumor-Infiltrating Lymphocytes as a Surrogate Biomarker for PD-L1 -- Immune checkpoint inhibitors -- Screening programs for breast cancer -- Transversal perspectives of integrative oncology care -- Assessment and response to neoadjuvant treatments -- Precision surgery for the treatment of breast cancer -- A precise approach for radiation therapy of breast cancer -- Fast mimicking diets and other innovative nutritional interventions to treat patients with breast cancer -- Endocrine resistance of breast cancer -- Innovative therapeutic approaches for patients with HER2- positive breast cancer -- Management of patients with breast cancer and brain metastasis -- New concepts in cardio-oncology -- Clinical utility, cost-effectiveness, and budgetary impact of next-generation sequencing in metastatic breast cancer -- ONCOLLEGE-001: The global landscape on the access to cancer medicines for breast cancer. 330 $aThis book focuses on innovative treatment options for breast cancer, including surgery, radiotherapy, systemic therapy and of course immunotherapy that is changing outcomes in some aggressive breast cancer histotypes. Subsequent chapters also address the ongoing emerging research in the screening, diagnostics, and management of all subtypes of breast cancers. All current landscapes and future perspectives in each molecular subtype: luminal, HER2-positive, and triple-negative breast cancers are discussed within the different chapters. Breast cancer is still the most common cancer and cause of cancer deaths among women worldwide. The improvement of breast cancer outcome appears to be strictly related to the validation of precise biomarkers that enable us to better select personalized approaches in breast cancer management. The closing chapters deal with the challenges of low income countries of conducting research in the era of precision medicine forcancer. The book is edited and authored by leading experts in this field and will be of interest for clinicians and scientists alike. 410 0$aCancer Treatment and Research,$x2509-8497 ;$v188 606 $aOncology 606 $aGynecology 606 $aCancer 606 $aOncology 606 $aGynecology 606 $aCancer Biology 615 0$aOncology. 615 0$aGynecology. 615 0$aCancer. 615 14$aOncology. 615 24$aGynecology. 615 24$aCancer Biology. 676 $a616.9944906 702 $aAl Jarroudi$b Ouissam 702 $aEl Bairi$b Khalid 702 $aCurigliano$b Giuseppe 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910799252203321 996 $aBreast cancer research and treatment$92200562 997 $aUNINA